Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
phase trials, announced the first dosing in a Phase II multicenter trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is acting as the full-service CRO for this trial. MDD is estimated to affect over 17 million adults in the United States, with approximately 30% of these patients being resistant to treatment. Supernus Pharmaceuticals , in collaboration with Navitor Pharmaceuticals , is developing SPN-820 to provide a rapid-onset antidepressant response via oral administration for adult patients with treatment-resistant depression. The compound has a novel mechanism of action that enhances synaptic activity and cellular metabolism in the brain and has demonstrated a rapid onset of action (signal at two hours) in previous clinical studies. Unlike other rapid-onset compounds currently approved or in clinical development, SPN-820 aims to provide rapid antidepressant efficacy without potential dissociative and neurological side effects. Jonathan Rubin, M.D., Supernus
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNAccesswire
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024GlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNPR Newswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNAccesswire
SUPN
Earnings
- 2/27/24 - Miss
SUPN
Sec Filings
- 4/24/24 - Form 8-K
- 4/24/24 - Form 8-K
- 4/8/24 - Form 8-K
- SUPN's page on the SEC website